Multiple myeloma partners

The Institute of Cancer Research and Cancer Research Technology Ltd. are collaborating with Janssen Research & Development of Johnson & Johnson to modulate the unfolded protein response in multiple myeloma. Although no particulars have been disclosed by the partners, previous results from the U.K. team have suggested the kinase domain of IRE1 as a potential target in the pathway.

CRT is the commercial arm of Cancer Research UK (CRUK), a cancer charity that funds research, including at the ICR.

Standard of care for multiple myeloma (MM) includes the immunomodulatory drugs Thalomid thalidomide and Revlimid lenalidomide from Celgene Corp. and the proteasome inhibitor Velcade bortezomib

Read the full 1026 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers